ProfileGDS5678 / 1426939_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 74% 75% 73% 75% 78% 75% 74% 74% 74% 74% 74% 77% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.909475
GSM967853U87-EV human glioblastoma xenograft - Control 24.8362474
GSM967854U87-EV human glioblastoma xenograft - Control 34.9032275
GSM967855U87-EV human glioblastoma xenograft - Control 44.8732173
GSM967856U87-EV human glioblastoma xenograft - Control 55.04375
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1840378
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8964175
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8256374
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8417974
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8744674
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8835174
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8381874
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1435977
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.043676